ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,564.41
1.08%
US Tech 100
19,255.20
1.29%
Dow Jones
40,415.44
0.32%
Brent Oil
81.525
0.01%
Bitcoin
67,576.60
-0.04%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Affimed NV (AFMD)

  7. Affimed NV (AFMD) News

AFMD

Affimed NV (AFMD)

Affimed NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AFMD
DateTimeSourceHeadlineSymbolCompany
06/12/20247:56AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
06/12/20247:13AMIH Market NewsU.S. Futures Rise on Fed Decision; Oil Gains on Demand ForecastsNASDAQ:AFMDAffimed NV
06/12/20246:30AMGlobeNewswire Inc.Affimed Reports First Quarter 2024 Financial Results & Business UpdateNASDAQ:AFMDAffimed NV
06/06/20245:13PMEdgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:AFMDAffimed NV
06/05/20246:30AMGlobeNewswire Inc.Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024NASDAQ:AFMDAffimed NV
06/03/20246:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
06/01/20241:02PMGlobeNewswire Inc.Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortNASDAQ:AFMDAffimed NV
05/29/20246:30AMGlobeNewswire Inc.Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung CancerNASDAQ:AFMDAffimed NV
05/28/20246:51AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
05/28/20246:30AMGlobeNewswire Inc.Affimed Announces Annual General Meeting of ShareholdersNASDAQ:AFMDAffimed NV
05/23/20245:22PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
05/23/20245:05PMGlobeNewswire Inc.Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024NASDAQ:AFMDAffimed NV
05/14/202410:05AMGlobeNewswire Inc.Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 CongressNASDAQ:AFMDAffimed NV
04/24/20244:05AMGlobeNewswire Inc.Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyNASDAQ:AFMDAffimed NV
03/28/20246:30AMGlobeNewswire Inc.Affimed Reports 2023 Financial Results and Operational ProgressNASDAQ:AFMDAffimed NV
03/21/20246:30AMGlobeNewswire Inc.Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024NASDAQ:AFMDAffimed NV
03/11/20244:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
03/06/20246:34AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
03/06/20246:30AMGlobeNewswire Inc.Affimed Announces 1-for-10 Reverse Stock SplitNASDAQ:AFMDAffimed NV
01/08/20244:45PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
01/08/20244:05PMGlobeNewswire Inc.Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerNASDAQ:AFMDAffimed NV
01/08/20248:11AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
01/08/20248:00AMGlobeNewswire Inc.Affimed Announces Leadership Change and Organizational RestructuringNASDAQ:AFMDAffimed NV
01/03/20246:30AMGlobeNewswire Inc.Affimed Announces Sale of Wholly-Owned Subsidiary AbCheckNASDAQ:AFMDAffimed NV
12/11/20236:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
12/11/20236:02AMGlobeNewswire Inc.Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer PatientsNASDAQ:AFMDAffimed NV
12/11/20236:00AMGlobeNewswire Inc.Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)NASDAQ:AFMDAffimed NV
12/04/20236:30AMGlobeNewswire Inc.Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24NASDAQ:AFMDAffimed NV
11/30/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
11/14/20236:30AMGlobeNewswire Inc.Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressNASDAQ:AFMDAffimed NV
 Showing the most relevant articles for your search:NASDAQ:AFMD

Your Recent History

BIT
OAT5L
Solactive leveraged long...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved